The Centers for Medicare & Medicaid Services recently issued a guidance warning about the dangers of opioid-induced respiratory depression (“OIRD”) and required the following actions be taken: Timely ...
STAMFORD, Conn.--(BUSINESS WIRE)--Purdue Pharma L.P. (“Purdue”) today announced The Journal of Clinical Pharmacology has published findings from a study in healthy adult volunteers that demonstrated ...
This head-to-head pharmacodynamic study in healthy volunteers examined the ability of both OPVEE and intranasal naloxone to reverse opioid-induced respiratory depression, which is the shallow and slow ...
Respiratory depression has been associated with the use of opioid analgesics. However, a recent study by researchers at Wesley Medical Center in Wichita, Kan., suggests exhaled CO2 monitoring of ...
RED BANK, NJ / ACCESS Newswire / August 20, 2025 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company dedicated to developing innovative therapeutic ...
Nearly 75 percent of hospitalized patients receiving opioids for pain management are not monitored according to hospital guidelines. A study led by University at Buffalo nursing researcher Carla ...
Brixadi (buprenorphine) is a brand-name injection that’s prescribed for opioid use disorder. As with other drugs, Brixadi can cause side effects, such as injection site reactions and respiratory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results